These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18097807)

  • 1. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.
    Gao L; Zhang D; Chen M; Zheng T; Wang S
    Drug Dev Ind Pharm; 2007 Dec; 33(12):1332-9. PubMed ID: 18097807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
    Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
    Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin.
    Li C; Zhang D; Guo H; Hao L; Zheng D; Liu G; Shen J; Tian X; Zhang Q
    Int J Pharm; 2013 May; 448(1):79-86. PubMed ID: 23518367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antitumor activity of oridonin nanosuspension.
    Lou H; Zhang X; Gao L; Feng F; Wang J; Wei X; Yu Z; Zhang D; Zhang Q
    Int J Pharm; 2009 Sep; 379(1):181-6. PubMed ID: 19563872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine.
    Hecq J; Deleers M; Fanara D; Vranckx H; Amighi K
    Int J Pharm; 2005 Aug; 299(1-2):167-77. PubMed ID: 15996838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
    Karakucuk A; Celebi N; Teksin ZS
    Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
    Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
    Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
    Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
    Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension.
    Feng FF; Zhang DR; Tian KL; Lou HY; Qi XL; Wang YC; Duan CX; Jia LJ; Wang FH; Liu Y; Zhang Q
    Drug Deliv; 2011 May; 18(4):265-71. PubMed ID: 21091387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
    Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
    Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
    Thakkar HP; Patel BV; Thakkar SP
    J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo.
    Xing J; Zhang D; Tan T
    Int J Biol Macromol; 2007 Jan; 40(2):153-8. PubMed ID: 16901536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies on glycerol monooleate- and phytantriol-based cubosomes containing oridonin in vitro and in vivo.
    Shi X; Peng T; Huang Y; Mei L; Gu Y; Huang J; Han K; Li G; Hu C; Pan X; Wu C
    Pharm Dev Technol; 2017 May; 22(3):322-329. PubMed ID: 26670780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.
    Lou H; Gao L; Wei X; Zhang Z; Zheng D; Zhang D; Zhang X; Li Y; Zhang Q
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):319-25. PubMed ID: 21676599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.